best syringe for retatrutide Dosage Guide 2026: Phase 3 TRIUMPH Data Retatrutide Delivers Bariatric-Level Weight Loss

PMID: 265 LucateliRLSilvaPHFSalvadorSLErvolinoEFurlanetoFACMarcianoMAet al

The DEA and most state medical boards now allow licensed physicians to evaluate, prescribe, and follow up on weight-loss medications entirely over telehealth no in-person visit required, no prior relationship needed, no insurance contract

Cancers (Basel) 12, 1

Dulaglutide appears to have one of the lower rates of nausea among GLP-1 receptor agonists

The expiry of semaglutide patents in India and Canada (January 2026) and Brazil (March 2026) opens the doors for affordable alternatives to penetrate emerging markets, where obesity and diabetes are growing public health challenges

Not everyone in healthcare is fully supportive yet, but thats changing as more research emerges and more of us share our lived experiences